{"disease":{"id":"third-line-and-beyond-therapy","name":"third line and beyond therapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07085169","title":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06728852","title":"Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Li-kun Chen","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}